PB2023: THE LEVEL OF VASCULAR ENDOTHELIAL FACTOR (VEGF) IN THE BLOOD SERUM OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS RAEB I).

PB2023: THE LEVEL OF VASCULAR ENDOTHELIAL FACTOR (VEGF) IN THE BLOOD SERUM OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS RAEB I).

Bibliographic Details
Main Authors:	Галина Стародуб, Olga Basova, Nadiya Goryainova, Nataliia Tretiak
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000974900.73193.9d

Similar Items

PB1807: THE SIGNIFICANCE OF MOLECULAR RISK FACTORS IN ACUTE MYELOID LEUKEMIA
by: Alla Gordienko, et al.
Published: (2023-08-01)

Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990-99.
by: Webb, D, et al.
Published: (2002)

Serum vascular endothelial growth factor (vegf) as a biomarker of lupus nephritis
by: Iberahim, Rahimah
Published: (2013)

Trisomy X and myelodysplastic syndrome (MDS) with eosinophilia
by: Mohd Tohit, Eusni Rahayu, et al.
Published: (2012)

Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor Inhibitors in Health and Disease
by: Sylvain Broussy
Published: (2024-07-01)

Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
by: Daniel Karel, et al.
Published: (2024-04-01)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
by: Josephine Lucero, et al.
Published: (2023-06-01)

PB2564: COVID-19 AND FERRITIN
by: Bohdana Kuiavovych, et al.
Published: (2023-08-01)

The importance of serum and pleural fluid level of vascular endothelial growth factor (VEGF) and VEGF fluid/serum ratio in the differential diagnosis of malignant mesothelioma-related pleural effusion
by: Yakup Düzköprü, et al.
Published: (2017-09-01)

PB2670: EQOL-MDS TRIAL: PATIENT-REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA.
by: Esther Oliva, et al.
Published: (2023-08-01)

Transformation of myelodysplastic syndrome (MDS) to acute myeloid leukaemia (AML)
by: Goh, Chermaine Yu Zhen
Published: (2021)

EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT
by: Sabine Blum, et al.
Published: (2021-09-01)

Molecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance
by: Fieke W. Hoff, et al.
Published: (2023-02-01)

P743: THE PIVOTAL ROLE OF GLUTAMINOLYSIS IN MYELODYSPLASTIC SYNDROME (MDS): A NOVEL STRATEGY FOR THE TARGETED THERAPY OF MDS
by: S. Okabe, et al.
Published: (2022-06-01)

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
by: Stahl, M, et al.
Published: (2023)

THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (t-MDS) IN CHILDHOOD: THE EXPERIENCE OF THE HELLENIC STUDY GROUP FOR MDS/JMML/SAA, MEMBER OF THE EWOG-MDS/SAA WORKING GROUP
by: Loizos Petrikkos, et al.
Published: (2023-12-01)

“Low‐risk” myelodysplastic neoplasm (MDS): Time for a name change?
by: Shoshana Burke, et al.
Published: (2025-01-01)

Qualitative flow cytometric analysis of Malaysian myelodysplastic syndromes (MDS) patients.
by: Broojerdi, Mohadese Hashem, et al.
Published: (2012)

Adults Myelodysplastic Syndromes in Algeria: A Study by the Algerian MDS Group
by: Mohamed Amine Bekadja, et al.
Published: (2023-04-01)

Current State and Challenges in Development of Targeted Therapies in Myelodysplastic Syndromes (MDS)
by: Michele Stanchina, et al.
Published: (2021-04-01)

Role of Copper and Vascular Endothelial Growth Factor (VEGF) on Endometrial Angiogenesis
by: Yousef Rezaei Chianeh, et al.
Published: (2013-07-01)

Vascular Endothelial Growth Factor (VEGF) and Its Role in the Cardiovascular System
by: Kamila Florek, et al.
Published: (2024-05-01)

PB1999: TOBACCO SMOKING IN MDS PATIENTS – ANALYSIS FROM THE MDS PALG REGISTRY
by: Rafal Machowicz, et al.
Published: (2023-08-01)

PB1922: EFFECTIVENESS OF AZACITIDINE IN FRONTLINE HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A RETROSPECTIVE COHORT STUDY OF 382 PATIENTS
by: N. Rajakumaraswamy, et al.
Published: (2022-06-01)

New insights into PSAT1 as a therapeutic target for myelodysplastic syndrome (MDS)
by: Sael Alatawi, et al.
Published: (2024-01-01)

Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
by: Cristina A. Tentori, et al.
Published: (2024-05-01)

Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?
by: Cristina Maria Failla, et al.
Published: (2024-12-01)

MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS)
by: Chen, J, et al.
Published: (2022)

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
by: Theo de Witte, et al.
Published: (2020-09-01)

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
by: Efficace, F, et al.
Published: (2024)

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
by: Fabio Efficace, et al.
Published: (2024-05-01)

PB2016: HIGH SERUM FERRITIN LEVELS AT DIAGNOSIS PREDICT WORSE PROGNOSIS IN ADVANCED MDS IN CHILDREN.
by: Chenmeng Liu, et al.
Published: (2023-08-01)

DHPLC analysis of the ATRX gene in myelodysplastic syndrome (MDS) associated with acquired alpha thalassemia (AT-MDS): Novel mutation detection despite somatic mosaicism.
by: Steensma, D, et al.
Published: (2003)

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome (MDS)
by: Botezatu, L, et al.
Published: (2016)

P108: Myelodysplastic syndrome (MDS) detected by germline genetic testing for hereditary cancer
by: Larissa Peck, et al.
Published: (2024-01-01)

The Clinical Impact of Vascular Endothelial Growth Factor/Receptor (VEGF/R) Inhibitors on Voice
by: Christina Hui Lee Ng, et al.
Published: (2023-01-01)

Automated and Reproducible Detection of Vascular Endothelial Growth Factor (VEGF) in Renal Tissue Sections
by: Nayana Damiani Macedo, et al.
Published: (2019-01-01)

Vascular endothelial growth factor (VEGF) emerging as a mediator of hereditary angioedema (HAE)
by: Pedro Giavina-Bianchi, MD, PhD, et al.
Published: (2024-08-01)

Increase in Vascular Endothelial Growth Factor (VEGF) Expression and the Pathogenesis of iMCD-TAFRO
by: Gordan Srkalovic, et al.
Published: (2024-06-01)

Role of Vascular Endothelial Growth Factor (VEGF) in Human Embryo Implantation: Clinical Implications
by: Xi Guo, et al.
Published: (2021-02-01)